Mylan Inc (MYL)
MYL (NASDAQ:Drugs)
$31.18
-0.58
-1.81%
Today's Range: 31.04 - 31.69 |
MYL Avg Daily Volume: 6,211,200
| Last Update: 05/24/13 - 4:00 PM EDT |
| Volume: 5,952,812 |
| YTD Performance: 15.66%
|
| Open: $31.69 |
| Previous Close: $31.75 |
| 52 Week Range: $20.50 -
$32.09 |
| Oustanding Shares: 381,089,535 |
| Market Cap: 12,099,592,736 |
6-Month Chart
TheStreet Ratings Grade for MYL
| Buy |
Hold
|
Sell
|
| A+ |
A |
A- |
B+ |
B |
B- |
C+ |
C |
C- |
D+ |
D |
D- |
E+ |
E |
E- |
F |
Analysts Ratings
| Historical Rec |
Current |
1 Mo. Ago |
2 Mo. Ago |
3 Mo. Ago |
| Strong Buy |
7 |
7 |
8 |
10 |
| Moderate Buy |
1 |
1 |
1 |
1 |
| Hold |
5 |
6 |
5 |
4 |
| Moderate Sell |
1 |
1 |
1 |
1 |
| Strong Sell |
0 |
0 |
0 |
0 |
| Mean Rec. |
2.00 |
2.07 |
1.93 |
1.75 |
| Latest Dividend: |
0.06 |
| Latest Dividend Yield: |
0.00% |
| Dividend Ex-Date: |
06/27/07 |
| Price Earnings Ratio: |
21.03 |
|
| Price Earnings Comparisons: |
| MYL |
Sector Avg. |
S&P 500 |
| 21.03 |
21.20 |
17.70 |
| Price Performance History (%Change): |
| 3 Mo |
1 Yr |
3 Y |
|
9.56%
|
49.23%
|
62.74%
|
|
| GROWTH |
12 Mo |
3 Yr |
CAGR |
| Revenue |
10.90 |
0.33 |
0.10 |
| Net Income |
19.80 |
1.76 |
0.40 |
| EPS |
24.60 |
3.97 |
0.70 |
| Earnings for MYL: |
| EBITDA |
1.65B |
| Revenue |
6.80B |
|
Average Earnings Estimates
;Qtr (09/13);FY (12/13);FY (12/14)&HEADING_LIST1=Qtr (06/12);Qtr (09/12);FY (12/12);FY (12/13)) |
|
| Average Estimate |
$0.68 |
$0.89 |
$2.88 |
$3.27 |
| Number of Analysts |
9 |
8 |
10 |
10 |
| High Estimate |
$0.68 |
$0.92 |
$2.91 |
$3.57 |
| Low Estimate |
$0.67 |
$0.85 |
$2.85 |
$3.14 |
| Prior Year |
$0.60 |
$0.83 |
$2.59 |
$2.88 |
| Growth Rate (Year over Year) |
12.59% |
7.23% |
11.35% |
13.42% |
Mar 25, 2013 | 6:51 AM EDT
MYL was downgraded from Outperform to Market Perform, Bernstein said. $33 price target. Company lacks near-term catalysts.
Mar 13, 2013 | 6:57 AM EDT
Barclays Healthcare Conference
| Mar 11, 2013 | 9:30 AM EDT
Here is how I am picking apart the sectors looking for strong relative performance candidates.
Mar 11, 2013 | 8:36 AM EDT
MYL was downgraded to Neutral, said Canaccord. Fewer catalysts are ahead, making upside from here limited.
Nov 28, 2012 | 8:14 AM EST
Shares of MYL now seen reaching $31, according to Canaccord Genuity. Estimates also upped, as the company will likely make an accretive...
| Nov 21, 2012 | 1:00 PM EST
The health sector is one the less-beaten-down areas amid market weakness.
Nov 16, 2012 | 8:07 AM EST
MYL was upgraded to Outperform from Market Perform, Leerink Swann said. $30 price target. Improved outlook on EpiPen and accretive tran...
Oct 26, 2012 | 6:50 AM EDT
MYL was upgraded to Buy, Canaccord Genuity said. $30 price target. Company can deliver earnings upside in the coming quarters.
| Oct 01, 2012 | 11:00 AM EDT
Here are two generic-drug companies that should hold up well, regardless of the current uncertainty.
| Aug 10, 2012 | 11:45 AM EDT
There's no reason to read much into it.
